191 related articles for article (PubMed ID: 36014894)
1. Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy.
Ning K; Li Z; Liu H; Tian X; Wang J; Wu Y; Xiong L; Zou X; Peng Y; Zhou Z; Zhou F; Yu C; Luo J; Zhang H; Dong P; Zhang Z
Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014894
[TBL] [Abstract][Full Text] [Related]
2. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract][Full Text] [Related]
3. Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective study.
Wang J; Dong P; Qu Y; Xu W; Zhou Z; Ning K; Peng Y; Xiong L; Li Z; Zou X; Liu Z; Li M; He Z; Luo J; Tian X; Zhang H; Guo S; Han H; Zhou F; Yin S; Ye D; Yu C; Zhang Z
Eur Radiol; 2023 May; 33(5):3232-3242. PubMed ID: 36538073
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
5. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2023 Jul; 84(1):109-116. PubMed ID: 36707357
[TBL] [Abstract][Full Text] [Related]
6. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
7. Perirenal Fat Thickness Is Significantly Associated With the Risk for Development of Chronic Kidney Disease in Patients With Diabetes.
Chen X; Mao Y; Hu J; Han S; Gong L; Luo T; Yang S; Qing H; Wang Y; Du Z; Mei M; Zheng L; Lv X; Tang Y; Zhao Q; Zhou Y; He JC; Li Q; Wang Z
Diabetes; 2021 Oct; 70(10):2322-2332. PubMed ID: 34593536
[TBL] [Abstract][Full Text] [Related]
8. Para-perirenal fat thickness is associated with reduced glomerular filtration rate regardless of other obesity-related indicators in patients with type 2 diabetes mellitus.
Xu S; Ma J; Zheng Y; Ren R; Li W; Zhao W; Ma Y; Zhou T; Zhang Y
PLoS One; 2023; 18(10):e0293464. PubMed ID: 37883495
[TBL] [Abstract][Full Text] [Related]
9. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents.
Ladoire S; Bonnetain F; Gauthier M; Zanetta S; Petit JM; Guiu S; Kermarrec I; Mourey E; Michel F; Krause D; Hillon P; Cormier L; Ghiringhelli F; Guiu B
Oncologist; 2011; 16(1):71-81. PubMed ID: 21212435
[TBL] [Abstract][Full Text] [Related]
10. Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma.
Aslan V; Kılıç ACK; Sütcüoğlu O; Eraslan E; Bayrak A; Öksüzoğlu B; Tahtacı G; Özdemir N; Üner A; Günel N; Özet A; Yazıcı O
Urol Oncol; 2022 Nov; 40(11):494.e1-494.e10. PubMed ID: 36137881
[TBL] [Abstract][Full Text] [Related]
11. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma.
Drljevic-Nielsen A; Donskov F; Mains JR; Andersen MB; Thorup K; Thygesen J; Rasmussen F
AJR Am J Roentgenol; 2022 May; 218(5):867-876. PubMed ID: 34910540
[No Abstract] [Full Text] [Related]
14. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
[TBL] [Abstract][Full Text] [Related]
15. Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study.
Massari F; Di Nunno V; Guida A; Costa Silva CA; Derosa L; Mollica V; Colomba E; Brandi G; Albiges L
Clin Genitourin Cancer; 2021 Feb; 19(1):32-40. PubMed ID: 32694008
[TBL] [Abstract][Full Text] [Related]
16. Body Composition in Relation to Clinical Outcomes in Renal Cell Cancer: A Systematic Review and Meta-analysis.
Vrieling A; Kampman E; Knijnenburg NC; Mulders PF; Sedelaar JPM; Baracos VE; Kiemeney LA
Eur Urol Focus; 2018 Apr; 4(3):420-434. PubMed ID: 28753824
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma.
Auclin E; Bourillon C; De Maio E; By MA; Seddik S; Fournier L; Auvray M; Dautruche A; Vano YA; Thibault C; Joly F; Brunereau L; Gomez-Roca C; Chevreau C; Elaidi R; Oudard S
Clin Genitourin Cancer; 2017 Jun; 15(3):350-355. PubMed ID: 28216276
[TBL] [Abstract][Full Text] [Related]
18. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy.
Grignol VP; Smith AD; Shlapak D; Zhang X; Del Campo SM; Carson WE
Surg Oncol; 2015 Dec; 24(4):353-8. PubMed ID: 26690825
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
20. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
